Sunday, Nov. 22, 2026 A Vik Media Group publication
Mongevity Longevity in Motion
Leer en español

New pre-surgery treatment shrank lung cancer tumors in most people in an early trial

☕ Includes a question for the family ↓

Lung cancerPart of a story we are following · 12 articles · See every update
Girl exercising side plank
Girl exercising side plankPhoto: Tyler Read / Wikimedia Commons, CC BY 2.0

If you or someone you love has ever worried about lung cancer, here is some steady news from research. A new treatment given before surgery is being tested, and early results show it shrank tumors a lot in most people. You cannot ask for it yet, but it shows where care may be heading.

In a phase 2 trial of 77 adults with lung cancer that could be removed by surgery, most people who got the drug ivonescimab with chemotherapy before their operation had a major response in the tumor. In that group, about 7 in 10 people had little or no living cancer left in the tissue removed.

How the study worked

Researchers tested a drug called ivonescimab in people with operable non-small cell lung cancer, the most common kind of lung cancer. It was given before surgery, either alone (10 people in the first group) or with chemotherapy (67 people in the second group), and then continued after surgery. This was an early-stage trial with no comparison group, so it shows promise but cannot yet say how the drug stacks up against current care. The results were published in Nature Medicine on November 4, 2026.

What they found

The main measure was something doctors call a major pathological response. It means that when surgeons removed the tumor and the lab looked at it, 10% or less of the tissue still held living cancer cells.

In the group that got ivonescimab plus chemotherapy, 70.1% (47 of 67 people) had this kind of response. The researchers had set a bar based on past results, about 41%, and this treatment cleared it. That means the main goal of the trial was met.

In the group that got ivonescimab alone, 60.0% (6 of 10 people) had a major response. That group was small, so it is hard to read much into the number.

The results went deeper for many people. Among those who had a major response, 97.9% (46 of 47) in the chemotherapy group had 5% or less living tumor left. In the ivonescimab-only group, 83.3% (5 of 6) did.

Safety matters too. Serious side effects (grade 3 or higher) linked to the treatment happened in 30.4% (24 of 79) of people in the chemotherapy group and 36.4% (4 of 11) in the ivonescimab-only group. No one had serious bleeding, and no one died from the treatment. Surgery was delayed because of treatment in one person (1.3%). Problems around surgery related to the drug showed up in 10.4% (7 of 67) and 10.0% (1 of 10) of people in the two groups, and none were serious.

What does “before surgery” treatment mean?

Doctors call this neoadjuvant therapy. The idea is to start treatment first to shrink the tumor, then operate, then keep going with treatment to lower the chance the cancer comes back. For lung cancer that can be removed, coming back after surgery is a real concern, which is why researchers keep looking for better ways to combine treatment and surgery.

What you can do today

Ivonescimab is still being studied, so there is nothing to request at the pharmacy. What you can do is learn how to find trials. Spend a few minutes on ClinicalTrials.gov, type in “non-small cell lung cancer,” and see what studies are open near you. This trial is listed there as NCT05247684.

Talk about it at home

Scientists are trying out a new way to take care of people with a lung illness, and they begin carefully with a small group before many more people are involved. It is like testing a new recipe on your family before cooking it for a big party: you taste, you adjust, and you learn what works. That patient, step-by-step testing is how researchers find out what is helpful and what is safe.

Ask a grandparent or another older person what outdoor games they played as a kid that left them out of breath and laughing, and whether anyone in the neighborhood could hold their breath the longest.

Try it at home

Also cited: ClinicalTrials.gov

Keep exploring

Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.

Got a question? Ask us ›

Get the best of longevity science by emailThe most useful new studies, in plain language and with the source. Free.

We'll email you once to confirm. Occasional messages from our sponsors, clearly labeled. Unsubscribe anytime. We never ask for health data.
Cite this article
AMA
Mongevity Desk. New pre-surgery treatment shrank lung cancer tumors in most people in an early trial. Mongevity. Published November 11, 2026. Accessed November 22, 2026. https://mongevity.science/cancer/2026/11/ivonescimab-before-surgery-lung-cancer-trial/
Vancouver
Mongevity Desk. New pre-surgery treatment shrank lung cancer tumors in most people in an early trial [Internet]. Mongevity; 2026 Nov 11 cited 2026 Nov 22]. Available from: https://mongevity.science/cancer/2026/11/ivonescimab-before-surgery-lung-cancer-trial/
APA
Mongevity Desk. (2026, November 11). New pre-surgery treatment shrank lung cancer tumors in most people in an early trial. Mongevity. https://mongevity.science/cancer/2026/11/ivonescimab-before-surgery-lung-cancer-trial/
For your website
<a href="https://mongevity.science/cancer/2026/11/ivonescimab-before-surgery-lung-cancer-trial/">New pre-surgery treatment shrank lung cancer tumors in most people in an early trial</a>

Free to share or quote with credit and a link.

Questions and answers

Can I get ivonescimab now?
No. In this study it was still being tested in a trial, so it is not something you can ask for yet.
What is a major pathological response?
It means that after surgery, the lab found 10% or less living cancer in the removed tumor tissue.
How many people were in the trial?
Ten people got ivonescimab alone and 67 got it with chemotherapy, for an early-stage trial.
Were there serious side effects?
Some people had serious side effects, about 3 in 10 in the chemotherapy group. None had serious bleeding or died from the treatment.

Sources

  1. Nat Med: Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial (PMID 42982996 · DOI 10.1038/s41591-026-04745-4) · 2026-11-11

More on this story

Report an error